Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382
Stopped Because of many competing trials using the same mechanism of action, but being further advanced in development
Conditions
- Chronic Hepatitis C Infection
Interventions
- DRUG: Placebo
- DRUG: JNJ-47910382
Sponsor
Janssen R&D Ireland